Please assess the completion status of the following clinical trial:

Trial Title: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven relapsed or refractory low-grade or follicular CD+ non-Hodgkin lymphoma, including 1 of the following:~  * Small lymphocytic lymphoma~ * Lymphoplasmacytoid lymphoma~ * Follicular center lymphoma (grades I, II, and III)~ * Extranodal marginal zone B-cell lymphoma~ * Nodal marginal zone B-cell lymphoma~ * Splenic marginal zone B-cell lymphoma (monocytoid B-cell lymphoma)~* Less than 25% bone marrow involvement of cellular marrow with lymphoma by bilateral bone marrow aspirate and biopsy~* ECOG performance status 0-2~* Bidimensionally measurable disease with at least 1 lesion \>= 2 cm in the greatest diameter~* No prior myeloablative therapy with autologous or allogeneic bone marrow transplantation or peripheral blood stem cell support~* No concurrent corticosteroid therapy, except prednisone (or equivalent) for adrenal failure or \< 20mg of prednisone daily~* No prior external beam radiotherapy to \>25% of active bone marrow~* More than 4 weeks since prior surgery other than diagnostic surgery~* No other concurrent myelosuppressive antineoplastic agents~* No prior radioimmunotherapy, including yttrium Y 90 ibritumomab tiuxetan or iodine I 131 monoclonal antibody tositumomab or Lym-1~* No CNS lymphoma~* No myelodysplastic syndromes or marrow chromosomal changes suggesting myelodysplasia~* No HIV or AIDS-related lymphoma~* No pleural effusion or ascites with lymphoma cells~* No active infection~* No other serious non-malignant disease that would preclude study participation~* No other active primary malignancy~* No known human anti-mouse or human anti-chimeric antibody~* No prior skin rash (e.g., Stevens-Johnsons syndrome or toxic epidermal necrolysis) from rituximab therapy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Absolute neutrophil count \>= 1,500/mm\^3~* Platelet count \>= 150,000/mm\^3~* Total lymphocyte count \< 5,000/mm\^3 for patients with small lymphocytic lymphoma~* Bilirubin =\< 2 mg/dL~* Creatinine =\< 2 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (radiolabeled monoclonal antibody therapy) (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.

Based on this trial design, predict the completion outcome and termination type (if applicable).